Thai Q. Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thai Q. Tran has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Mei Kong
Department of Molecular Biology and Biochemistry, Charlie Dunlop School of Biological Sciences, University of California Irvine, Irvine, USA
3 shared publications Ying Yang
Department of Molecular Biology and Biochemistry University of California, Irvine Irvine CA USA
3 shared publications- Eric A. Hanse
Department of Molecular Biology and Biochemistry, Charlie Dunlop School of Biological Sciences, University of California Irvine, Irvine, USA
2 shared publications - Haiqing Li
Integrative Genomics Core, Department of Shared Resources, Beckman Research Institute, City of Hope, Duarte, USA
2 shared publications Mari B. Ishak Gabra
Department of Molecular Biology and Biochemistry; School of Biological Sciences, University of California, Irvine, Irvine, USA
2 shared publicationsXazmin H. Lowman
Department of Molecular Biology and Biochemistry; School of Biological Sciences, University of California, Irvine, Irvine, USA
2 shared publications
Latest Publications
- 7 July 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (8) , e51910
The B56α subunit of PP2A is necessary for mesenchymal stem cell commitment to adipocyte
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 7 July 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (8) , e51910
The B56α subunit of PP2A is necessary for mesenchymal stem cell commitment to adipocyte
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 3 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth
Tumour cells adapt to nutrient deprivation in vivo, yet strategies targeting the nutrient poor microenvironment remain unexplored. In melanoma, tumour cells often experience low glutamine levels, which promote cell dedifferentiation. Here, we show that dietary glutamine supplementation significantly inhibits melanoma tumour growth, prolongs survival in a transgenic melanoma mouse model, and increases sensitivity to a BRAF inhibitor. Metabolomic analysis reveals that dietary uptake of glutamine effectively increases the concentration of glutamine in tumours and its downstream metabolite, αKG, without increasing biosynthetic intermediates necessary for cell proliferation. Mechanistically, we find that glutamine supplementation uniformly alters the transcriptome in tumours. Our data further demonstrate that increase in intra-tumoural αKG concentration drives hypomethylation of H3K4me3, thereby suppressing epigenetically-activated oncogenic pathways in melanoma. Therefore, our findings provide evidence that glutamine supplementation can serve as a potential dietary intervention to block melanoma tumour growth and sensitize tumours to targeted therapy via epigenetic reprogramming.
- 3 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
Open AccessDietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth
Tumour cells adapt to nutrient deprivation in vivo, yet strategies targeting the nutrient poor microenvironment remain unexplored. In melanoma, tumour cells often experience low glutamine levels, which promote cell dedifferentiation. Here, we show that dietary glutamine supplementation significantly inhibits melanoma tumour growth, prolongs survival in a transgenic melanoma mouse model, and increases sensitivity to a BRAF inhibitor. Metabolomic analysis reveals that dietary uptake of glutamine effectively increases the concentration of glutamine in tumours and its downstream metabolite, αKG, without increasing biosynthetic intermediates necessary for cell proliferation. Mechanistically, we find that glutamine supplementation uniformly alters the transcriptome in tumours. Our data further demonstrate that increase in intra-tumoural αKG concentration drives hypomethylation of H3K4me3, thereby suppressing epigenetically-activated oncogenic pathways in melanoma. Therefore, our findings provide evidence that glutamine supplementation can serve as a potential dietary intervention to block melanoma tumour growth and sensitize tumours to targeted therapy via epigenetic reprogramming.
- 20 March 2020
- Published by Springer Nature in Nature Cancer
- Vol. 1 (3) , 345-358
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer
Genetic-driven deregulation of the Wnt pathway is crucial but not sufficient for colorectal cancer (CRC) tumorigenesis. Here, we show that environmental glutamine restriction further augments Wnt signaling in APC-mutant intestinal organoids to promote stemness, and leads to adenocarcinoma formation in vivo via decreasing intracellular α-ketoglutarate (αKG) levels. αKG supplementation is sufficient to rescue low-glutamine-induced stemness and Wnt hyperactivation. Mechanistically, we found that αKG promotes hypomethylation of DNA and histone H3K4me3, leading to an upregulation of differentiation-associated genes and downregulation of Wnt target genes, respectively. Using organoids derived from patients with CRC and several in vivo CRC tumor models, we show that αKG supplementation suppresses Wnt signaling and promotes cellular differentiation, thereby significantly restricting tumor growth and extending survival. Together, our results reveal how the metabolic microenvironment impacts Wnt signaling and identify αKG as a potent antineoplastic metabolite for potential differentiation therapy for patients with CRC.
- 20 March 2020
- Published by Springer Nature in Nature Cancer
- Vol. 1 (3) , 345-358
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer
Genetic-driven deregulation of the Wnt pathway is crucial but not sufficient for colorectal cancer (CRC) tumorigenesis. Here, we show that environmental glutamine restriction further augments Wnt signaling in APC-mutant intestinal organoids to promote stemness, and leads to adenocarcinoma formation in vivo via decreasing intracellular α-ketoglutarate (αKG) levels. αKG supplementation is sufficient to rescue low-glutamine-induced stemness and Wnt hyperactivation. Mechanistically, we found that αKG promotes hypomethylation of DNA and histone H3K4me3, leading to an upregulation of differentiation-associated genes and downregulation of Wnt target genes, respectively. Using organoids derived from patients with CRC and several in vivo CRC tumor models, we show that αKG supplementation suppresses Wnt signaling and promotes cellular differentiation, thereby significantly restricting tumor growth and extending survival. Together, our results reveal how the metabolic microenvironment impacts Wnt signaling and identify αKG as a potent antineoplastic metabolite for potential differentiation therapy for patients with CRC.